A TP-dependent chromatin remodeling complexes use energy derived from ATP hydrolysis to transiently displace nucleosomes at gene regulatory regions and, thereby, impact target gene expression.
A TP-dependent chromatin remodeling complexes use energy derived from ATP hydrolysis to transiently displace nucleosomes at gene regulatory regions and, thereby, impact target gene expression. 1 These nimble epigenetic machines are well suited for facilitating dynamic gene expression changes, such as those that occur during embryonic development. 2 Global deletion of the ATPase catalytic subunits of these complexes in mouse embryos can result in early and lethal developmental defects because of misexpression of genes required for cell lineage commitment or survival. [3] [4] [5] Cellspecific deletion of these ATPases further indicates their capacity to mediate consequential target gene expression changes at specific times and locations in a developing embryo. [6] [7] [8] Deletion of the gene encoding the mammalian Switch/ Sucrose Nonfermentable chromatin remodeling complex ATPase BRG1 (brahma-related gene 1; also known as Smarca4) using a Tie2-Cre + transgene that is expressed in endothelial and hematopoietic cells has revealed roles for this chromatin remodeling enzyme in early vascular patterning and venous specification. [9] [10] [11] BRG1 promotes transcription of Wnt receptors and target genes in yolk sac endothelial cells, and Brg1 fl/ fl ;Tie2-Cre + embryos have abnormal yolk sac vascular patterning by embryonic day 9.5 (E9.5) because of downregulation of these Wnt signaling pathway genes. 10 In addition, BRG1 promotes expression of the transcription factor COUP-TFII (chicken ovalbumin upstream promoter transcription factor 2, also known as NR2F2), which is required for embryonic venous specification, and Brg1 fl/fl ;Tie2-Cre + mutants display aberrant arterial markers on their veins by E10.5. 11 However, excision of Brg1 from Tie2 + primitive erythrocytes results in primitive erythrocyte apoptosis, anemia, and lethality by E11.5 9 ; therefore, Brg1 fl/fl ;Tie2-Cre + embryos cannot yield information about roles for BRG1 in later stages of vascular development.
To bypass this lethality and study the role of BRG1 in vascular development beyond E11.5, we previously used a constitutive vascular endothelial cadherin (VE-Cadherin)-Cre line, which is fully penetrant in endothelial cells by E14.5.
12 Brg1
fl/fl ;VECadherin-Cre + embryos survived development and displayed no consistent vascular anomalies, but we did not detect robust embryonic endothelial cell BRG1 depletion in this model. 13 Therefore, in the current study, we exploited the Cdh5(PAC)-Cre ERT2 line, which is expressed in endothelial cells after tamoxifen induction, 14 to produce more complete embryonic endothelial cell Brg1 deletion. As detailed later, Brg1
embryos reveal new information about a temporally specific role for BRG1 in establishing vascular integrity by promoting SRF (serum response factor) signaling in capillary endothelial cells.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Figure 1A and 1B). Blood was also occasionally observed at the tip of the mutant embryonic tails. Transverse histological sections stained with hematoxylin and eosin revealed that the pools of blood observed grossly in mutant embryos correlated with dilated blood vessels rather than vascular rupture ( Figure 1C  through 1H ).
Results

E12.5
Further analysis of E12.5 embryonic tissue sections immunostained for the endothelial cell marker endomucin revealed that capillaries in the neck and limb buds were significantly dilated in Brg1 fl/fl ;Cdh5(PAC)-Cre ERT2 embryos, but larger vessels (ie, the dorsal aortae and posterior cardinal veins) were not aberrantly dilated (Figure 2A 18 results in dilated head, neck, and yolk sac capillaries and lethality by E14.5. 19 These phenotypes likely arise from transcriptional misregulation of SRF target genes involved in endothelial cell junctions and are restricted to capillaries because SRF is not expressed in endothelial cells of larger blood vessels at midgestation. 17 Incidentally, we also see stronger expression of BRG1 in endothelial cells of small vessels versus large vessels at E12.5 ( Figure VI in ;Cdh5(PAC)-Cre ERT2 embryos. We found both transcripts significantly downregulated in isolated yolk sac endothelial cells and limb buds from mutant embryos ( Figure 3A and 3B). Finally, when we knocked down BRG1 in the murine C166 yolk sac endothelial cell line with siRNA oligos, we once again detected significant downregulation of transcripts for Srf, its coregulators Mrtfa and Mrtfb, and its endothelial cell target genes VE-Cadherin, Zo-1, and β-actin ( Figure 3C ).
We next coimmunostained tissue sections from E12. 
Mrtfa and Mrtfb Are Direct Targets of BRG1 in Embryonic Endothelial Cells
To determine whether BRG1 directly promotes transcription of Srf, its cofactor genes, or its target genes, we next performed chromatin immunoprecipitation for BRG1 in C166 endothelial cells. We amplified DNA immunoprecipitated with a BRG1 antibody for selected conserved regions of the promoters of Srf, Mrtfa, Mrtfb, and the Srf target genes β-actin, Cx43 (also known as Gja1), VE-Cadherin, and Zo-1. Among these potential BRG1 target genes, we only saw evidence of BRG1 binding at the Mrtfa and Mrtfb promoters ( Figure 4 ; Figure X in the online-only Data Supplement). We next used luciferase reporter assays to test the functional impact of BRG1 expression on Mrtfa, Mrtfb, and Srf transcription. We generated luciferase reporters containing fragments of the Mrtfa or Mrtfb promoters that included the region in which we detected positive BRG1 binding by chromatin immunoprecipitation. We also made a reporter containing 1.5 kb of the Srf promoter. On BRG1 knockdown, we saw a significant decrease in activity for all 3 of these luciferase reporters ( Figure 5A ). Conversely, BRG1 overexpression significantly elevated reporter activity for all 3 constructs ( Figure 5B ). The changes seen in the Srf promoter reporter assays surprised us because our chromatin immunoprecipitation assays did not reveal BRG1 binding to the region of the Srf promoter used in this reporter construct. However, we suspect that these changes are secondary to the transcriptional impact on MRTF-A/B seen with BRG1 knockdown or overexpression because SRF can autoregulate its own expression, 21, 22 presumably with the help of MRTF-A/B.
Finally, to assess whether exogenous expression of MRTF-A/B could rescue expression of Srf and SRF target genes in BRG1 knockdown endothelial cells, we generated MRTF-A and MRTF-B expression vectors and confirmed their ability to generate protein ( Figure XI in the online-only Data Supplement). When we overexpressed these cofactors individually or in combination with SRF in C166 endothelial cells, we were able to rescue expression of Srf and the SRF target genes β-actin and Zo-1, which were diminished in BRG1 knockdown cells ( Figure 5C ). Altogether, these data indicate that BRG1 regulates expression of Srf and SRF target genes in embryonic endothelial cells by promoting transcription of the SRF cofactors MRTF-A and MRTF-B ( Figure 6 ).
Discussion
SRF is a ubiquitously expressed transcription factor that contributes to a variety of cellular processes and is essential for embryonic viability. 23 SRF binds DNA at CArG box motifs, which are located in the promoters of >200 experimentally validated target genes. 24 Although SRF has low transcriptional activity on its own, it can interact with over 60 different cofactors that modulate its transcriptional potential in response to cellular stimuli or in specific cell types. 25, 26 The MRTF-A and MRTF-B coactivators are important modulators of SRF transcriptional activity. 27 Rho signaling and actin dynamics regulate the ability of these cofactors to access the nucleus and coactivate SRF-dependent expression of target genes that promote myogenic differentiation and cytoskeletal organization. MRTF-A and MRTF-B have been intensely studied in the context of smooth muscle cells, but knockouts for these broadly expressed genes indicate that they play important roles in coregulating SRF signaling in other cell types as well. 28 In endothelial cells, MRTF-A/MRTF-B and SRF are required for normal postnatal retinal angiogenesis and for maintenance of cerebral small vessel integrity. cell-specific genes. 30, 31 Although our new data do not rule out a similar role for BRG1 in promoting SRF-mediated expression of endothelial cell adhesion genes through direct MRTF-A or MRTF-B binding, we do find that overexpression of MRTF-A/B in the C166 yolk sac-derived endothelial cell line is sufficient to elevate expression of SRF target genes even in the absence of BRG1 ( Figure 5C , or Srf (serum response factor; C) promoters. Input DNA was isolated from chromatin prior to IP and was used to confirm PCR efficiency. H 2 O was amplified instead of DNA as a negative control for PCR. Promoter sequence conservation between mouse and other designated species was assessed using the NCBI DCODE website (http://www.dcode.org); peak heights indicate degree of sequence homology. Boxed regions indicate PCR amplicons selected for analysis and are labeled below according to their average distance from each transcription start site (TSS). Negative control amplicons (underlined) are not shown on the sequence alignments but were selected based on their greater distances from each TSS. D through F, PCR band densities from 3 independent experiments were quantified using ImageJ, normalized to IgG controls for each experiment, and combined. Data are presented as fold change over the IgG ChIP levels; error bars represent SD. Statistical calculations were performed using a 2-tailed Student t test (*P<0.05; **P<0.01; ns, not significant). 5 kb) , Mrtfb (2.5 kb), or Srf (serum response factor; 1.5 kb) promoters upstream of the respective transcription start sites were stably expressed in the HEK293T human embryonic kidney cell line. Stable lines were transfected with nonspecific control (NS) or BRG1 siRNA oligos (A) or with a BRG1 expression plasmid or its relevant empty vector control (B). Luciferase activity was measured 24 hours post-transfection and was normalized to activity from control samples. Error bars represent SD of results from 3 independent experiments (with triplicate samples). Statistical calculations were performed using a 2-tailed Student t test (*P<0.05). C, C166 endothelial cells (ECs) were transfected with nonspecific control or BRG1 siRNA oligos plus an empty vector (EV) or expression plasmids for murine MRTF-A, MRTF-B, or SRF for 24 hours. RNA was harvested, and quantitative reverse transcriptase polymerase chain reaction (qPCR) was performed to detect expression of Brg1, Srf, β-actin, and Zo-1 (zonula occludens-1). Data shown represent BRG1 knockdown samples, which were normalized to the relative expression of control nonspecific knockdown samples (dotted line). Error bars represent SD of results from 3 independent experiments. Statistical calculations were performed using a 1-way ANOVA comparing overexpression plasmid transfections against EV transfections for each transcript analyzed (*P<0.05).
detailed earlier, a 24-hour shift in induction (E10.5-12.5) had no effect on Mrtf expression and resulted in no obvious phenotypes (Figures IV and IX in the online-only Data Supplement). This suggests that some other factor compensates for BRG1 to promote Mrtfa/Mrtfb transcription in endothelial cells starting at E10.5. Clearly, MRTF-A and MRTF-B continue to be important cofactors for SRF-mediated transcription of genes required for small vessel development and integrity, as evidenced by the aberrant retinal angiogenesis and intracerebral hemorrhage seen in postnatal vascular Mrtfa/Mrtfb and Srf mutants. 20, 29 However, postnatal vascular Brg1 mutants do not share these phenotypes, 13 which provides further evidence that BRG1 regulates endothelial cell Mrtfa/Mrtfb expression specifically during midgestation.
This newly defined role for BRG1 in developing embryonic capillaries highlights the fascinating temporal/spatial specificity that chromatin remodeling factors exercise in selecting and regulating their target genes. In general, we find BRG1 to play transient roles in establishing early steps of blood vessel development and specification at midgestation, 9-11 but our work has not yet revealed long-term implications for BRG1 in maintaining or recapitulating those roles during postnatal vascular development. 13 This observation suggests that BRG1-mediated chromatin remodeling events that promote initial expression of key developmental genes pave the way for establishment of more stable covalent epigenetic marks (ie, histone acetylation) that sustain long-term gene expression. Indeed, we propose that covalent epigenetic marks provide a more energetically favorable way to sustain long-term gene expression than chromatin remodeling, which relies on ATP hydrolysis. In the context of the present study, we speculate that BRG1 remodels the Mrtf promoters to promote Mrtfa/b transcription in early capillary endothelial cells but that other covalent epigenetic marks maintain the protranscriptional status of the Mrtf promoters throughout the rest of embryogenesis and beyond birth. Future analysis of nucleosome condensation and epigenetic marks at the Mrtf promoters in embryonic and postnatal endothelial cells will be required to substantiate this hypothesis. 
